Investigational drug · Phase 3
IRX-101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Retinal Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "IRX-101"
First trial start
2023
Feb 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IRX-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Retinal Disease
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "IRX-101" as an intervention, largest first.
- Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal InjectionsPivotal-lookingNot yet recruiting
iRenix Medical, Inc.Industry
NCT05750589 · 240 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 31, 2027
Drug: IRX-101; Providone-Iodine · For: Retinal Disease
Sites: San Antonio, Texas
- SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)Pivotal-lookingCompleted
iRenix Medical, Inc.Industry
NCT05747430 · 155 participants · Start Feb 22, 2023 · Primary completion Mar 6, 2025
Drug: IRX-101; Providone-Iodine · For: Retinal Disease
Sites: Greenwich, Connecticut; Madison, Mississippi; Erie, Pennsylvania · 7 sites in all
- EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)Pivotal-lookingTerminated
iRenix Medical, Inc.Industry
NCT05127525 · 5 participants · Start Nov 15, 2021 · Primary completion Jan 31, 2022
Drug: IRX-101; Control · For: Diabetic Macular Edema; Branch Retinal Vein Occlusion; Glaucoma/Closed Angle Glaucoma
Sites: Tampa, Florida
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Retinal Disease
- sepofarsenQR-110Phase 32 trials
Laboratoires Thea · Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis
- Intravitreal of UltevursenPhase 22 trials
Laboratoires Thea · Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind
- QR-1123Phase 21 trial
ProQR Therapeutics · Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary
- VP-001Phase 21 trial
PYC Therapeutics · Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.